Population pharmacokinetic analysis of pegylated human erythropoietin in rats

Journal of Pharmaceutical Sciences

Volumn 93, Issue 12, 2004, Pages 3027-3038

  Jolling, Koen ^a   Perez Ruixo, Juan Jose ^a   Hemeryck, Alex ^a   Piotrovskij, Vladimir ^a   Greway, Tony ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bootstrap analysis; Nonlinear mixed effects modeling; Pegylated human erythropoietin; Population pharmacokinetics; Rat

Indexed keywords

ERYTHROPOIETIN; PEGYLATED ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; MALE; MODEL; NONHUMAN; NONPARAMETRIC TEST; POPULATION; PREGNANCY; RAT; SEX DIFFERENCE; TOXICOKINETICS;

EID: 10644276313     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20200     Document Type: Article

References (18)

1. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
2. Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261-1277.
3. Fung WJ, Porter JE, Bailon P. 1997. Strategies for the preparation and characterization of polyethylene glycol (PEG) conjugated pharmaceutical proteins. Polym Preprint 38:565-566.
4. Harris JM, Martin NE, Modi M. 2001. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551.
5. Hing J, Woolfrey SG, Greenslade D, Wright PMC. 2002. Distinguishing animal subsets in toxicokinetic studies: Comparison of non-linear mixed effects modelling with non-compartmental methods. J Appl Toxicol 22:437-443.
6. Bouzom F, Laveille C, Merdjan H, Jochemsen R. 2000. Use of non-linear mixed effects modeling for the meta-analysis of preclinical pharmacokinetic data: Application to S20342 in the rat. J Pharm Sci 89:603-613.
7. Williams PJ, Ette EI. 2000. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's "Guidance for Industry: Population pharmacokinetics." Clin Pharmacokinet 39:385-395.
8. Lindstrom MJ, Bates TM. 1990. Nonlinear mixed effects models for repeated measures. Biometrics 46:673-687.
9. Beal SL, Boeckmann A, Sheiner LB. 1988-1998. NONMEM users guides - Part I-VIII, NONMEM Project Group C2555. San Francisco: University of California at San Francisco.
10. S-Plus professional release. 2000. Seattle: Mathsoft, Inc., Data Analysis Products Division.
11. Ramakrishnan R, Cheung WK, Farell F, Kelley ML. Jolliffe L, Jusko WJ. 2003. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous single dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 306:324-331.
12. Efron B, Tibshirani R. 1993. An introduction to the bootstrap. London: Chapman and Hall.
13. Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A. 1992. Pharmacokinetics and distribution of recombinant erythropoietin in rats. Arzneimittelforschung 42:174-178.
14. Gough SR, Mosher MD, Conrad KP. 1995. Metabolism of erythropoietin in conscious pregnant rats. Am J Physiol 68:R1117-R1120.
15. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126.
16. Mahmood I, Balian JD. 1999. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokinet 36:1-11.
17. Retout S, Mentre F, Bruno R. 2002. Fisher information matrix for non-linear mixed-effects models: Evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat Med 21:2623-2639.
18. Green B, Duffull S. 2003. Prospective evaluation of a D-optimal designed population pharmacokinetic study. J Pharmacokinet Pharmacodyn 30:145-161.